Response Genetics, Inc. (RGI) was founded in 1999 to leverage breakthrough, patented technology from USC for the extraction of genetic information from formalin-fixed, paraffin-embedded clinical trial samples. Until that time, it was not possible to extract meaningful genetic information from standard diagnostic specimens.
Our success in developing this technology allows us to deliver tangible benefits to physicians and pharmaceutical companies and to support the development of more personalized patient therapies in an efficient, cost-effective manner.
To provide timely, accurate, and validated diagnostic testing services to physicians and pharmaceutical companies that enable personalized cancer treatment.
Response Genetics has client relationships with some of the largest pharmaceutical companies in the world including: